Balanced news tone
News Sentiment
BIIB sentiment intelligence
Biogen Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
33 relevant articles
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+3.7% over one week, +8.3% over four weeks, trend active, and materially above fair value.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
81/100 classification
One-week reaction
3.7%
Price confirming higher
Trend fit
Trend active
8.3% over four weeks
Fair value
41.1%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
24
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Yahoo! Finance Canada
Direct company coverage
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 14:51
- Source
- Yahoo! Finance Canada
Stock Titan
Direct company coverage
Biogen's incoming legal chief has 20 years in biotech leadership
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 12:15
- Source
- Stock Titan
Clinical Trials Arena
Direct company coverage
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:38
- Source
- Clinical Trials Arena
Market source
Direct company coverage
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jul 2026 02:11
- Source
- Market source
Investor's Business Daily
Direct company coverage
Biogen Dips As Questions Weigh On Alzheimer's 'Breakthrough'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:13
- Source
- Investor's Business Daily
Barron's
Direct company coverage
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:09
- Source
- Barron's
Fierce Biotech
Direct company coverage
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:00
- Source
- Fierce Biotech
qz.com
Direct company coverage
Biogen stock falls 8% on Alzheimer's drug diranersen trial data
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Jul 2026 17:42
- Source
- qz.com
Quiver Quantitative
Direct company coverage
Biogen slides as investors reassess Alzheimer’s data and earnings overhang
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 14:51
- Source
- Quiver Quantitative
Market source
Direct company coverage
How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 14:14
- Source
- Market source
Market source
Direct company coverage
Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 Jul 2026 13:48
- Source
- Market source
Barron's
Direct company coverage
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
- Tone
- Positive 84/100
- Event
- Analyst action
- Published
- 13 Jul 2026 18:32
- Source
- Barron's
Market source
Direct company coverage
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Why Biogen (BIIB) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Traders Union
Direct company coverage
Biogen stock price forecast: $174.41 support comes into view as BIIB slips 1.94%
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 19 Jun 2026 07:00
- Source
- Traders Union
Market source
Direct company coverage
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
Biogen
Direct company coverage
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Tone
- Positive 95/100
- Event
- Guidance
- Published
- 31 Mar 2026 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Completes Acquisition of Alcyone Therapeutics
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Nov 2025 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 23 Sep 2025 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Aug 2025 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2025 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Completes Acquisition of Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 26 Sep 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen to Acquire Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 Jun 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 27 Jan 2022 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Nov 2020 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Aug 2020 07:00
- Source
- Biogen